MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway

Acute myeloid leukemia (AML) is the most lethal form of AML due to disease relapse. Cyclin dependent kinase 8 (CDK8) is a serine/threonine kinase that belongs to the family of Cyclin-dependent kinases and is an emerging target for the treatment of AML. MK256, a potent, selective, and orally availabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jen-Chieh, Liu, Shu, Wang, Yucheng, Liang, You, Jablons, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629815/
https://www.ncbi.nlm.nih.gov/pubmed/36342456
http://dx.doi.org/10.18632/oncotarget.28305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629815/
https://www.ncbi.nlm.nih.gov/pubmed/36342456
http://dx.doi.org/10.18632/oncotarget.28305

Ejemplares similares